In this study, we found that pancreatic cancer cells expressing high levels of MAP17 showed increased sensitivity to some drugs, such as gemcitabine, 5-fluorouracil, cisplatin, or osimertinib, an EGFR inhibitor, in vitro. This evidence concerns the gene EGFR and pancreatic neoplasm.